Rheumatoid arthritis, gene therapy

Kang, C. P. et al., The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis, Rheumatology (Oxford), 44, 547, 2005. 

Kumagai, K., Hiyama, K., Oyama, T., Maeda, H., and Kohno, N. (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. International Journal of Molecular Medicine. 11, 593-600. 

Mugnier, B., Balandraud, N., Darque, A., Roudier, C., Roudier, J., and Reviron, D. (2003) Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis and Rheumatism. 48, 1849-1852. 

Gene therapy holds great promise for the treatment of many diseases (e.g., cancer, AIDS, cystic fibrosis, adenosine deaminase deficiency, cardiovascular diseases, Gaucher disease, a 1-antitrypsin deficiency, rheumatoid arthritis, and several others) (1,2). Advances in genomics and molecular biology have revealed that almost all diseases have a genetic component. In some cases, such as cystic fibrosis or hemophilia,... 

Muller-Ladner U, Gay S. The SCID mouse—a novel experimental model for gene therapy in human rheumatoid arthritis. Drugs Today (Barcelona) 1999 35 379-88. 

Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF et al (2008) Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis Rheumatol Int 28 901-908... 

---